Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
SAN DIEGO, March 08, 2018 -- Vical Incorporated (Nasdaq:VICL) today announced that the company will report financial results for the three months ended December 31, 2018, before the opening of trading on Thursday, March 15, and conduct a conference call and webcast to discuss the financial results and provide a company update at noon Eastern Time on Thursday, March 15. The call will be open on a listen-only basis to any interested parties. The company will also provide a business update, including details on development programs in the conference call and webcast.
Conference Call
To listen to the conference call, dial in approximately ten minutes before the scheduled call to (323) 994-2083 (preferred), or (800) 562-8369 (toll-free), and reference confirmation code 2848082. A replay of the call will be available for 48 hours beginning about two hours after the call. To listen to the replay, dial (719) 457-0820 (preferred) or (888) 203-1112 (toll-free) and enter replay passcode 2848082. The call also will be available live and archived through the events page at www.vical.com.
Invited participants may ask questions during the conference call. Others may submit questions before the call by e-mail addressed to [email protected] or by fax to (858) 646-1150. Submitted questions will be screened for appropriateness and general interest. Selected questions received with sufficient notice before the call will be answered as time permits at the end of the call. For further information, contact Vical’s Investor Relations department by phone at (858) 646-1127 or by email at [email protected].
About Vical
Vical develops biopharmaceutical products for the prevention and treatment of chronic or life-threatening infectious diseases, including antiviral and antifungal candidates in clinical development. Additional information on Vical is available at www.vical.com.
Contact:
Andrew Hopkins
(858) 646-1127
Website: www.vical.com
